Boehringer Ingelheim Pharmaceuticals, Inc., recently released a report highlighting the first batch of findings based on 49 idiopathic pulmonary fibrosis patients enrolled in the IPF-PRO Registry — an academic-industry partnership between Boehringer and the Duke ... Read more